Lung transplantation

UTHealth Surgeons at Memorial Hermann First in Texas to Perform Double Lung Transplant On Patient Whose Lungs Were Damaged By COVID-19

Thursday, September 17, 2020 - 12:18am

HOUSTON, Sept. 16, 2020 /PRNewswire/ --UTHealthtransplant surgeons at Memorial Hermann were the first in Texas to perform a double lung transplant on a 70-year-old man whose lungs were severely damaged by COVID-19.

Key Points: 
  • HOUSTON, Sept. 16, 2020 /PRNewswire/ --UTHealthtransplant surgeons at Memorial Hermann were the first in Texas to perform a double lung transplant on a 70-year-old man whose lungs were severely damaged by COVID-19.
  • "At that point, we determined that the only way he would survive was if he underwent a double lung transplant."
  • More than 2,700 lung transplants were performed in the United States in 2019 and approximately two-thirds of those were double lung transplants.
  • Jyothula said that patients survive longer when receiving a double lung transplant as opposed to a single lung transplant.

Boomer Esiason Foundation Launches 7th Bike 2 Breathe

Tuesday, September 15, 2020 - 4:15pm

The entire Bike 2 Breathe team plans to follow a strict set of safety guidelines, from pre-event testing to daily temperature checks, among others.

Key Points: 
  • The entire Bike 2 Breathe team plans to follow a strict set of safety guidelines, from pre-event testing to daily temperature checks, among others.
  • Jerry Cahill is a cystic fibrosis patient and double lung transplant recipient who acts as an ambassador to the cystic fibrosis community for the Boomer Esiason Foundation.
  • In 1993, Gunnar Esiason son of former NFL MVP quarterback Boomer Esiason was diagnosed with cystic fibrosis.
  • Boomer and his wife Cheryl founded the Boomer Esiason Foundation to raise funds and awareness for the cystic fibrosis community.

TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference

Tuesday, September 1, 2020 - 9:30pm

ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference.

Key Points: 
  • ANDOVER, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be virtually participating in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference.
  • The fireside chat will take place on Thursday, September 17, 2020 at 8:00 a.m. EDT.
  • TransMedics is the worlds leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.
  • Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

H1 2020 Lung Transplant Rejection - Pipeline Review - ResearchAndMarkets.com

Monday, August 17, 2020 - 10:18am

The "Lung Transplant Rejection - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lung Transplant Rejection - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

TransMedics to Present at the Canaccord 40th Annual Growth Conference

Tuesday, July 28, 2020 - 9:01pm

ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference.

Key Points: 
  • ANDOVER, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (TransMedics) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be presenting at the virtual Canaccord 40th Annual Growth Conference.
  • The presentation will take place on Thursday, August 13, 2020 at 10:00 a.m. EDT.
  • TransMedics is the worlds leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation.
  • Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases

Thursday, June 18, 2020 - 1:00pm

Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1.

Key Points: 
  • Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1.
  • ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.
  • This funding will be instrumental in progressing our clinical programs in patients suffering from chronic lung diseases, including patients with a lung transplant, cystic fibrosis (CF), and non-CF bronchiectasis.
  • The company is focused on developing ARINA-1 for orphan chronic inflammatory lung diseases.

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

Tuesday, June 16, 2020 - 9:01pm

Dr. Martinezs interests include chronic obstructive pulmonary disease (COPD), interstitial lung disease, lung transplantation, and lung volume reduction.

Key Points: 
  • Dr. Martinezs interests include chronic obstructive pulmonary disease (COPD), interstitial lung disease, lung transplantation, and lung volume reduction.
  • Ms. Barnes is a research advocate who is an ally for patients suffering from lung and fibrotic diseases.
  • miRagen undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.
  • Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

TELUS Health, Saskatchewan Health Authority, and eHealth Saskatchewan Are Now Supporting Lung Transplant Patients Recovering at Home, Virtually

Thursday, June 11, 2020 - 3:00pm

REGINA, Saskatchewan, June 11, 2020 (GLOBE NEWSWIRE) -- TELUS Health today announced the expansion of its Home Health Monitoring (HHM) solution to digitally monitor the recovery of lung transplant patients across Saskatchewan.

Key Points: 
  • REGINA, Saskatchewan, June 11, 2020 (GLOBE NEWSWIRE) -- TELUS Health today announced the expansion of its Home Health Monitoring (HHM) solution to digitally monitor the recovery of lung transplant patients across Saskatchewan.
  • Launched in partnership with the Saskatchewan Health Authority and eHealth Saskatchewan, this digital health dashboard enables a virtual healthcare team to provide medical support remotely, for patients in real-time as they recover in their own homes.
  • It is estimated that the TELUS Health HHM solution and lung transplant monitoring program will support 60 to 70 Saskatchewanians for the lifetime of their transplant.
  • The launch of the HHM solution for transplant patients is another collaboration between TELUS Health and Saskatchewans public health system.

Daniel R. Goldstein, MD, Named Incoming Editor-in-Chief of the Journal of Heart and Lung Transplantation

Tuesday, May 12, 2020 - 7:52pm

ADDISON, Texas, May 12, 2020 (GLOBE NEWSWIRE) -- The International Society for Heart and Transplantation, which publishes theJournal of Heart and Lung Transplantation, named Daniel R. Goldstein, MD, the new editor-in-chief of the Journal.

Key Points: 
  • ADDISON, Texas, May 12, 2020 (GLOBE NEWSWIRE) -- The International Society for Heart and Transplantation, which publishes theJournal of Heart and Lung Transplantation, named Daniel R. Goldstein, MD, the new editor-in-chief of the Journal.
  • I am truly honored and very excited to become the next editor-in-chief of theJournal of Heart and Lung Transplantation,said Dr. Goldstein.
  • Dr. Goldsteins priorities for the Journal include making it the premier translational medicine journal in all areas related to advanced lung disease and extracorporeal support, advanced heart failure and mechanical circulatory support, lung and heart transplantation and pulmonary hypertension.
  • The International Society for Heart and Lung Transplantation is a not-for-profit, multidisciplinary professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies.

OneLegacy, Donate Life Hollywood and Recent Double-Lung Recipient Travis Flores Launch Video Series to Promote the Importance of Organ, Eye and Tissue Donation

Thursday, May 7, 2020 - 10:31pm

OneLegacy is launching a new four-part short video series and public service announcement to promote the importance of organ, eye and tissue donation.

Key Points: 
  • OneLegacy is launching a new four-part short video series and public service announcement to promote the importance of organ, eye and tissue donation.
  • The series is written and produced by Travis Flores, who received his third double-lung transplant earlier this week.
  • This is the third time that OneLegacy has worked with Flores to write and produce PSAs about donation.
  • Additionally, Donate Life Hollywood will share the PSA on their social media channels and through the DLH Activate App.